Pharma tycoon's wealth got boost as his generics maker Cadila Healthcare reported a 47% jump in net earnings in a recent quarter thanks to soaring sales in the U.S. Shares of the $1.3 billion (revenues) firm rose in July after it received U.S. FDA approval to sell a drug to treat chronic pain. Last December Cadila launched a low-cost version of Humira, AbbVies' arthritis drug. The firm denied reports that it was negotiating to buy the injectables business of rival Claris Life Sciences.